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Recently, it has been shown that a NO synthase (NOS) is present in rat liver mitochondria (14) . Monoclonal antibody studies have localized NOS to the mitochondria of rat hearts (3, 10) as well as skeletal muscle (11) . Mitochondrial NOS might provide a local source of NO that could be an effective modulator of oxidative phosphorylation even with a cytosol rich in myoglobin. The sensitivity of NOS to Ca 2ϩ (7) [a putative regulator of oxidative phosphorylation (15) ] as well as other metabolites including NADPH (8) suggests that NOS could play an important role in the regulatory network controlling aerobic ATP production in the heart.
The purpose of this study was to determine whether NOS was present in porcine heart mitochondria and whether it could be induced to generate a sufficient amount of NO to modify oxidative phosphorylation. This was accomplished by evaluating several substrates and inhibitors of NOS on aerobic respiration in isolated porcine heart mitochondria. In addition, direct assays of NO production as well as NOS protein and activity were performed on this preparation.
MATERIALS AND METHODS
Cardiac mitochondria preparation. Porcine heart mitochondria were isolated as previously reported (15) . Isolated mitochondria had a respiratory quotient (state 3 respiration/ state 4 respiration) of Ͼ10 using 5 mM glutamate and 5 mM malate as substrates (15) . Experiments were run in experimental buffer solution containing (in mM) 125 KCl, 15 NaCl, 20 HEPES, 1 EDTA, 1 EGTA, and 5 MgCl 2 and 800 M of total (535 nM free) Ca 2ϩ at pH 7. All experiments were run at 37°C. The concentration of mitochondria used in these studies was 1 nmol of cytochrome a (cyt a) per milliliter of buffer unless otherwise specified.
Cyt a and protein content. Mitochondria concentration was determined from the spectrophotometric determination of cyt a content as previously described (2) . Protein concentration was determined by biuret assay (9) with the modifications introduced by Yonetani (17) , and bovine serum albumin was used as a standard.
Monitoring of chamber O 2 and NO content. O2 consumption was monitored using a YSI Clark electrode (Yellow Springs, OH) that was calibrated to 100% air saturated at 37°C as previously described (12) . NO was simultaneously measured using a NO-selective electrode (WPI; Sarasota, FL) inserted into the water-jacketed chamber. The NO-selective electrode was calibrated using injections of nitrite into 0.1 M KI and 0.1 M H 2SO4.
Determination of L-citrulline. Porcine heart mitochondria were frozen and thawed three times using liquid nitrogen. An aliquot of these samples (containing 1-2 mg of protein/ml) was incubated (and constantly stirred) with 2 ml of solution containing 1 mM MgCl 2, 0.2 mM CaCl2, 30 M L-arginine, 0.1 mM NADPH, and 0.1 M triethanolamine (pH 7.4) supplemented with 10 M tetrahydrobiopterin. When N -monomethyl-L-arginine (L-NMMA) was used in the incubation instead of L-arginine, the mitochondrial protein concentration was 3-5 mg/ml. L-Citrulline produced during the NOScatalyzed reaction was measured using a colorimetric assay essentially as described by Prescott and Jones (13) .
SDS-PAGE analysis. Samples from porcine heart mitochondria were separated by SDS-PAGE using three 10% polyacrylamide gels. Samples were heated for 5 min at 95°C in a sample buffer that contained 10 mM Tris ⅐ HCl (pH 8.0), 1 mM EDTA, 2.5% (wt/vol) SDS, and 2.5% mercaptoethanol. The molecular weight markers (Amersham Life Science) were subjected to the same treatment as the samples before electrophoresis. After the samples were cooled, 0.01% (wt/vol) bromophenol blue was added, and 10 g of protein were loaded per lane. Gels were electrophoresed using a Bio-Rad (Hercules, CA) apparatus set at 200 V and 15 mA for 1 h at 4°C. For Western blot analysis, the proteins were blotted by electrodiffusion for 3 h at 40 V on nitrocellulose membranes (0.45-m pore size Trans-Blot membranes; Bio-Rad). Membranes were blocked with 5% bovine serum albumin and 10% normal goat serum in Tris-buffered saline (TBS; 150 mM NaCl and 10 mM Tris ⅐ HCl; pH 7.6) with 0.05% Tween 20 (TBST) for 1 h. The membranes were thoroughly washed with TBST and incubated separately with mouse monoclonal antibody to macrophage NOS (macNOS), neuronal NOS (nNOS), and endothelial NOS (eNOS) (1/2,000 dilution in TBST) for 1 h. The membranes were extensively washed with TBST and subsequently incubated with goat antibodies conjugated with horseradish peroxidase to mouse IgG (1/30,000, Upstate Biotech; Lake Placid, NY) for 1 h. After the membranes were washed with TBST, the immunocomplexes were developed using an enhanced horseradish peroxidase/luminol chemiluminescence reaction, which was detected with photographic film (Hyperfilm ECL; Amersham) and recorded after 10 s to 3 min of exposure. A lysate of mouse macrophage RAW 264.7 cell line, rat pituitary lysate, and human endothelial cells were used as positive controls for inducible NOS (iNOS), brain NOS (bNOS), and eNOS, respectively.
Chemical sources. NADPH, ADP, ATP, NO, L-citrulline, L-arginine, 2,3-butanedione monoxine, antipyrine, and L-NMMA were purchased from Sigma (St. Louis, MO). The antibodies to iNOS, nNOS, and eNOS were purchased from Transduction Laboratories (Lexington, KY). The antibodies to iNOS (or macNOS) were obtained using a 21-kDa protein fragment corresponding to amino acids 961-1,144 of mouse macNOS as immunogen. All other reagents were of analytical grade.
Statistical analysis. Data are expressed as means Ϯ SE. Statistical analysis was performed by one-way ANOVA.
RESULTS

Kinetics of NO inhibition of mitochondrial respiration.
To confirm that NO inhibits cardiac mitochondrial O 2 consumption, the effects of NO on cardiac mitochondria were first determined. NO was directly injected into the chamber with mitochondria while O 2 consumption and NO content were simultaneously monitored. An example from these studies is shown in Fig.  1A , where ADP (2 mM final concentration) and NO (1-4 M final concentration) were simultaneously injected into the chamber. With the injection of NO, the NO tension rapidly rose in the chamber and then quickly fell as it was metabolized. The NO was associ- ated with inhibition of the ADP-dependent increase in respiration as previously described (4) . As the NO was metabolized, the respiratory rate recovered in a dosedependent manner. These data could be used to calculate several factors involving NO kinetics in isolated heart mitochondria. First, the rate of NO metabolism in the presence of the mitochondria was determined and found to be linear with the [NO] . This suggests that the rate of metabolism is [NO] dependent. Because no saturation of this effect was observed, we assumed that this reaction was a pseudo-first-order reaction with regard to [NO] (in M) and mitochondria concentration, resulting in
where V NO is the rate of NO metabolism and k is the rate constant, which was determined to be 0.91 ϫ 10 Ϫ3 l ⅐ min Ϫ1 ⅐ nmol of cyt a Ϫ1 by performing a linear regression of the data in Fig. 1B . This mitochondrial NO metabolic rate constant can be extrapolated to the intact heart using cyt a conversion (37 nmol cyt a/g wet weight) (12) to 3.4 ϫ 10 Ϫ2 l ⅐ min Ϫ1 ⅐ g wet weight Ϫ1 . The concentration dependence of NO on mitochondrial inhibition can also be estimated from the experiments. By plotting the respiratory rate as a function of [NO], the concentration that results in 50% inhibition (I 50 ) of NO for respiration can be determined. The I 50 was ϳ0. 8 
M NO in two experiments (not shown).
Mitochondrial NO generation. Establishing the kinetics for NO inhibition in this preparation, we set out to determine whether mitochondrial NOS could generate sufficient NO to inhibit mitochondrial respiration and therefore regulate ATP production. To accomplish this, we used previously established procedures to generate NO from endogenous NOS using L-arginine. An example of the basic assay procedure is shown in Fig.  2A , where the effects of L-arginine could be assessed for both state 4 (no ADP) and state 3 (saturating ADP and P i ) respiration. Ca 2ϩ was added (535 nM free Ca 2ϩ ) to ensure activation of mitochondrial ATP production (15) as well as any Ca 2ϩ -sensitive NOS (7). There were no significant decreases in state 3 (2 mM ADP) or state 4 respiration with the addition of 3-300 M L-arginine (Fig. 2B) . In addition, no increase in NO generation was observed using the NO-sensitive electrode at any dose of L-arginine (not shown). These data are not consistent with the significant generation of NO by mitochondrial NOS under these circumstances. 4 . Equal protein amounts of porcine heart and rat liver mitochondria were loaded onto SDS-PAGE gels and electroblotted onto nitrocellulose membranes. Western blots were performed using monoclonal antibodies to inducible (iNOS), brain (bNOS) or neuronal (nNOS), and endothelial (eNOS) NOS. Positive controls were run using those provided by Transduction Laboratories.
To confirm this result, inhibitors of NOS were used to test whether the control respiratory rate was already under NO inhibition even in the absence of L-arginine. In addition, some NO production could be occurring in the mitochondrial matrix, which is not detected using the extramitochondrial NO electrode. To examine these possibilities, the NOS inhibitor L-NMMA (3-300 M) was used to block NOS generation of NO. L-NMMA had no effect on respiration during states 3 and 4 (Fig. 3) .
NOS activity and quantitation. Another method of monitoring NOS activity is to track the production of L-citrulline from L-arginine, which is cosynthesized with the production of NO by NOS (13). L-Citrulline was produced at a rate of 0.22 Ϯ 0.03 nmol ⅐ mg mitochondrial protein Ϫ1 ⅐ min Ϫ1 in heart mitochondria. This activity is 14-fold smaller than that found in rat liver mitochondria (8) . The pig heart mitochondria NOS activity was inhibited by L-NMMA and was negligible in the absence of L-arginine.
It was unclear whether this discrepancy with liver was due to NOS content or activity of the enzyme present. To discern these possibilities, Western blots of rat liver and pig heart mitochondria were performed for the direct comparison of enzyme contents. Western blots using monoclonal antibodies to bNOS, eNOS, and macNOS isoforms indicated that porcine heart mitochondria exhibited the same isoform as that found in rat liver mitochondria, a 100-to 130-kDa protein that is antigenically related to the macNOS isoform yet of constitutive expression. The protein band was about 10 times less intense than the band identified with rat liver mitochondria, which suggests that the specific activities of mitochondrial NOS from the heart and liver are probably equal and differ only in the content of mitochondrial enzyme (Fig. 4) .
DISCUSSION
The concentration of NOS in porcine heart mitochondria is ϳ10 times lower than in the rat liver based on Western blot assays as well as homogenate activity. NO production by NOS was not detected in mitochondria suspensions based on the lack of L-arginine-dependent or L-NMMA-sensitive NO production or any effect of these agents on oxidative phosphorylation. The discrepancy between the intact mitochondrial data and homogenate data is likely due to the rapid mitochondrial metabolism of NO. The NO metabolism was ϳ1-4 nmol ⅐ mg mitochondrial protein Ϫ1 ⅐ min Ϫ1 in the mitochondria, whereas the maximum rate of NO production in the homogenates was 0.22 nmol ⅐ mg mitochondrial protein Ϫ1 ⅐ min Ϫ1 based on L-citrulline production. This comparison suggests that any production of NO by mitochondrial NOS was immediately metabolized and resulted in undetectable levels of NO production. The fact that oxidative phosphorylation was not inhibited by NOS activity suggests that significant levels of NO were not being generated even in the mitochondrial matrix.
These data suggest that the small amount of NOS activity detected in heart mitochondria is unlikely to play a significant role in the regulation of oxidative phosphorylation due to the rapid metabolism of NO. It is possible that the NO metabolic rate in these isolated mitochondria is much higher than that occurring in the intact cell. However, no data on the in vivo rate of mitochondrial NO production or metabolism are currently available. All of these studies were conducted at extramitochondrial Ca 2ϩ concentrations near the optimal (ϳ500 nM free Ca 2ϩ ) for stimulating oxidative phosphorylation (15) . Studies were also conducted using Ca 2ϩ concentrations two-to threefold higher to test for a Ca 2ϩ -sensitive NOS; however, no evidence of NO production was detected even at these higher Ca 2ϩ levels.
The small amount of NOS detected in this mitochondrial preparation could be intimately associated with the mitochondria. The precise location within the mitochondrion is unknown, but with no NOS gene in the mitochondrial genome, its source must ultimately be the cytosol and a nuclear gene. A small cytosolic contamination causing the detection of NOS in this preparation cannot be ruled out. Enzymatic assays demonstrate that the preparation is highly purified based on the enrichment of the mitochondrial markers cyt a and citrate synthase. The levels of a cytosolic marker, phosphoglycerate kinase, in the preparation were Ͻ0.5% of the total tissue homogenate (not shown). Electron microscopy evaluation of the preparation also suggested very high purity based on visual inspection. However, these studies cannot rule out a small cytosolic contamination causing the residual NOS activity detected in this preparation.
In summary, these data suggest that the local production of NO by mitochondrial NOS is not significant even under optimal conditions and does not contribute to the regulation of oxidative phosphorylation in heart cells. If NO does play a role in the regulation of mitochondrial function, the NO must be reaching the mitochondria through the myoglobin-rich cytosol. This extramitochondrial NO production could be in the cytosol itself or from other cells (i.e., vascular endothelial cells) in the tissue. It is important to note that not all mitochondria in the myocytes are surrounded by myoglobin and that the subplasmalemma mitochondria could be almost immediately exposed to extracellular NO levels without myoglobin buffering. These mitochondria might be the most susceptible population to transient NO regulation of oxidative phosphorylation by vascular production.
